Key stats
About BMO MSCI GENOMIC INN INDEX ETF CAD UNIT
Expense ratio
0.47%
Home page
Inception date
Jan 14, 2021
The fund portfolio is comprised of companies whose business activities include gene editing, agricultural biotechnology, molecular diagnostics, genome related hardware for analytics and diagnostics, bioinformatics, targeted therapeutics, and gene and stem cell therapies. A stock relevance score is calculated by taking into account the portion of a companys revenue which is derived from the selected business segments, and those with a relevance score of 25% or more are eligible for inclusion in the index. Moreover, stocks are weighted by the product of their relevance score and their float-adjusted market-cap (subject to 5% capping). The fund is rebalanced semi-annually.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region